M2R lab is an R&D biotech company dedicated to develop innovative therapies to recover tissue and organ function in patients suffering from uncontrolled inflammation, a complication that leads to tissue degeneration and organ malfunction.
Despite the natural capacity of human tissues to restore damaged tissues, this process is often incomplete and scar or fibrotic tissue is formed permanently. Uncontrolled Inflammation associated to injuries promotes fibrosis reducing tissue function. Regenerative therapies, in order to be effective, should not only promote cell proliferation on damaged tissues but also reduce the fibrosis associated to the inflammatory process.
M2R therapies have a positive effect reducing fibrosis markers, being potential candidates for the treatment of fibrotic diseases.
Inflammation leading to irreversible tissue injury is mediated by macrophages, lymphocytes and cytokine release. Leukocyte phenotype is a key factor that modulate the regenerative process in injured tissues. Based on our knowledge on the role of immune cells on regeneration, and after various years studying the effect of these cells in injured organs, our approach is based on modifying leukocyte phenotype and function in order to promote tissue repair.
Our mission is to provide physicians and patients innovative therapeutic tools for the treatment of damaged tissue that are efficient and safe, using a best in class technology that is affordable. We work to cure better and more [people].
.
We search for blood cell therapies able to regenerate tissues.
Our therapies are focused on restoring damaged tissues that suffer a dysfunction, and on the inflammatory environment that supports them, in an attempt to impede their degeneration and death. We work to find new therapies that correct the pathological changes that are responsible for the disease, and to restore the initial structure of the tissue (i.e. regenerative medicine).
We specialize in developing therapies that promote the polarization of cells in order to change its behavior, promoting repair by integrating the latest advances in immunobiology with preclinical and clinical research.
of AKI patients need dialysis treatment
Mortality rate on ARDS patients
people suffer tendon injuries worldwide each year
Joaquín Juan is a Spanish physiotherapist specialized in the treatment of high-performance athletes, as well as a successful entrepreneur recognized in sports medicine. Joaquin is a pioneer in the design of a comprehensive health plan for top-level athletes that monitors, designs and covers all aspects related to the physical performance of the athlete. It is considered by experts and specialized magazines among the top three physiotherapists in the world. Joaquin is a founding partner, a key player in the creation and development of XCELL and actively involved in the design and implementation of the strategy of the Company.
Pablo Garcia de la Riva is an entrepreneur and executive with experience in the health industry with a strong interest in innovation and development of new products and businesses. It has over 20 years of experience in acquisitions and divestitures of companies and financial services and in management positions in the hospital and health companies. Pablo has a degree in Business Administration and holds an MBA from Boston College. Pablo has led the scientific team in the design of M2R business model, product portfolio development, management and planning of the company.
Georgina Hotter is an eminent biologist specialized in health sciences with more than 30 years of experience. Georgina is an expert in the areas of tissue regeneration, cell therapy, renal failure and acute kidney injury ischemia –reperfusion, transplants and organ preservation. She is a Principal Researcher at the Institute of Biomedical Research of Barcelona of the Spanish National Research Council (CSIC ) where she currently heads the Department Experimental Pathology. Gina holds a Bachelor’s and a Ph.D. in Biology from the University of Barcelona. She has leaded 16 national and 2 European R&D projects and her scientific production includes patents and publications, among others in Kidney International, World Journal of Surgery, the Journal of Pathology, the American Journal of Physiology, the journal of the American Transplant Society, between others. Georgina has led the team at CSIC that developed M2R breakthrough therapy.
Joaquín Juan is a Spanish physiotherapist specialized in the treatment of high-performance athletes, as well as a successful entrepreneur recognized in sports medicine. Joaquin is a pioneer in the design of a comprehensive health plan for top-level athletes that monitors, designs and covers all aspects related to the physical performance of the athlete. It is considered by experts and specialized magazines among the top three physiotherapists in the world. Joaquin is a founding partner, a key player in the creation and development of XCELL and actively involved in the design and implementation of the strategy of the Company.
Pablo Garcia de la Riva is an entrepreneur and executive with experience in the health industry with a strong interest in innovation and development of new products and businesses. It has over 20 years of experience in acquisitions and divestitures of companies and financial services and in management positions in the hospital and health companies. Pablo has a degree in Business Administration and holds an MBA from Boston College. Pablo has led the scientific team in the design of M2R business model, product portfolio development, management and planning of the company.
Anna Sola is a biologist from Barcelona with over 20 years of professional experience in life sciences. She is a recognized scientist, excelling in the fields of tissue regeneration, cell therapy, ischemia-reperfusion, organ transplants and preservation, among others. As a researcher of the Spanish public health system, Anna has worked in some of the major research centers of CSIC. Among others the Institute of Biomedical Research of Barcelona (GRT), IDIBAPS and the Institute of Biomedical Research of Bellvitge (IDIBELL). Currently, Anna leads a research team in IDIBELL. Anna has been a key member of the team that initially created M2R therapy.
Xavier Ginesta is a chemist with more than 15 years of experience in applied research and management of intellectual property. Xavier has a PhD from the University of Barcelona and did postdoctoral studies at the University of Bristol. He has worked in the development of biological compounds for 6 years and as a knowledge transfer manager at the Spanish National Research Council (CSIC). Xavier brings a wealth of experience in the protection and management of M2RLAB’s industrial property rights and assets.
Georgina Hotter is an eminent biologist specialized in health sciences with more than 30 years of experience. Georgina is an expert in the areas of tissue regeneration, cell therapy, renal failure and acute kidney injury ischemia –reperfusion, transplants and organ preservation. She is a Principal Researcher at the Institute of Biomedical Research of Barcelona of the Spanish National Research Council (CSIC ) where she currently heads the Department Experimental Pathology. Gina holds a Bachelor’s and a Ph.D. in Biology from the University of Barcelona. She has leaded 16 national and 2 European R&D projects and her scientific production includes patents and publications, among others in Kidney International, World Journal of Surgery, the Journal of Pathology, the American Journal of Physiology, the journal of the American Transplant Society, between others. Georgina has led the team at CSIC that developed M2R breakthrough therapy.
Anna Sola is a biologist from Barcelona with over 20 years of professional experience in life sciences. She is a recognized scientist, excelling in the fields of tissue regeneration, cell therapy, ischemia-reperfusion, organ transplants and preservation, among others. As a researcher of the Spanish public health system, Anna has worked in some of the major research centers of CSIC. Among others the Institute of Biomedical Research of Barcelona (GRT), IDIBAPS and the Institute of Biomedical Research of Bellvitge (IDIBELL). Currently, Anna leads a research team in IDIBELL. Anna has been a key member of the team that initially created M2R therapy.
Xavier Ginesta is a chemist with more than 15 years of experience in applied research and management of intellectual property. Xavier has a PhD from the University of Barcelona and did postdoctoral studies at the University of Bristol. He has worked in the development of biological compounds for 6 years and as a knowledge transfer manager at the Spanish National Research Council (CSIC). Xavier brings a wealth of experience in the protection and management of M2RLAB’s industrial property rights and assets.
Santiago Lamas, MD, PhD and CSIC Research Professor, is internationally recognized for his studies on endothelial cell vasoactive factors, redox biology and the contribution of microRNAs and metabolism to organ fibrosis. His H index is 54 and his publications have been cited more than 11,000 times. Amongst other recent responsibilities, he was CBM Director (2012-2014) and Chair of the Biomedicine Panel in the Spanish State Research Agency (2017-2020).
Esteban Poch is Senior Consultant in Nephrology and Chief of the Nephrology Department of the Hospital Clínic Barcelona. Established Researcher at the Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), and Professor of Medicine at the Medical School, University of Barcelona. He is devoted to patient care focusing in Hypertension, Diabetes and Intensive Care Nephrology and has extensive research in primary and secondary hypertension and acute kidney injury.
Has 35 years of experience as Technician in the Pharmaceutical industry and research departments, (Antibioticos-Farma, SA and CNB-CSIC). She is specialized in the stem cell culture and development of innovative medicines, She served for seven years as Manufacturing Manager of Cell Therapy medicines in Cellerix, SA (Tigenix). In 2010 Rossana founded Gradocell, a consulting company providing technical, regulatory and quality advice, as well as support with the execution of product development projects in the field of biotechnology, Advanced Therapies and Innovative medicines,where she heads Management and the Technical Consulting team. She studied Biological Sciences at the Complutense University of Madrid and has completed a Master’s Degree in Production and Applied Quality.
Santiago Lamas, MD, PhD and CSIC Research Professor, is internationally recognized for his studies on endothelial cell vasoactive factors, redox biology and the contribution of microRNAs and metabolism to organ fibrosis. His H index is 54 and his publications have been cited more than 11,000 times. Amongst other recent responsibilities, he was CBM Director (2012-2014) and Chair of the Biomedicine Panel in the Spanish State Research Agency (2017-2020).
Esteban Poch is Senior Consultant in Nephrology and Chief of the Nephrology Department of the Hospital Clínic Barcelona. Established Researcher at the Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), and Professor of Medicine at the Medical School, University of Barcelona. He is devoted to patient care focusing in Hypertension, Diabetes and Intensive Care Nephrology and has extensive research in primary and secondary hypertension and acute kidney injury. His scientific production IF is higher than 680 in 114 articles. In addition, he has published reviews (> 10), editorials (> 10), books (3) and chapters of book (43).
Has 35 years of experience as Technician in the Pharmaceutical industry and research departments, (Antibioticos-Farma, SA and CNB-CSIC). She is specialized in the stem cell culture and development of innovative medicines, She served for seven years as Manufacturing Manager of Cell Therapy medicines in Cellerix, SA (Tigenix). In 2010 Rossana founded Gradocell, a consulting company providing technical, regulatory and quality advice, as well as support with the execution of product development projects in the field of biotechnology, Advanced Therapies and Innovative medicines,where she heads Management and the Technical Consulting team. She studied Biological Sciences at the Complutense University of Madrid and has completed a Master’s Degree in Production and Applied Quality.
M2R has been funded by the Centre for the Development of Industrial Technology (CDTI), through the program NEOTEC, and the Ministry of Science and Innovation, through the program retos colaboracion 2019 ( RTC2019- 007197-1)
